GRAL Deadline Today: GRAIL Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Facts

Class Period: May 13, 2025 – Feb. 19, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Stock Drop: 50.55% in one session
Share Price Drop: $101.53 to $50.21
Market Cap Loss: Over $2.2 billion
Trial Endpoint: Primary endpoint not met

Background

Hagens Berman Sobol Shapiro LLP has alerted investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed. The firm is urging investors with substantial losses to submit their losses before the lead plaintiff deadline of August 4, 2026.

The class period runs from May 13, 2025, to February 19, 2026. The lawsuit alleges that GRAIL and certain senior executives misled investors regarding the clinical design, progress, and efficacy of its NHS-Galleri cancer screening trial.

Defendants reportedly asserted that the study was optimally structured with a three-year follow-up period to demonstrate a statistically significant reduction in late-stage (Stage III and IV) cancer diagnoses. The action centers on whether GRAIL selectively promoted favorable top-line results from initial screening rounds while withholding granular data and ignoring internal indicators suggesting that a three-year timeline would be insufficient to achieve the trial's primary endpoint.

Current Situation

On February 19, 2026, GRAIL announced top-line results from its NHS-Galleri trial. The company revealed that the trial failed to meet its primary endpoint of a statistically significant reduction in late-stage cancers. The company admitted that it 'probably should have allowed for a longer follow-up period.'

Following these disclosures, GRAL shares collapsed by 50.55% in a single trading session, plummeting from a close of $101.53 to $50.21 per share on February 20, 2026, erasing over $2.2 billion in market capitalization.

Hagens Berman has an ongoing investigation focusing on when GRAIL and its management first recognized that the required follow-up period diverged from the touted three-year duration. Reed Kathrein, the Hagens Berman partner leading the investigation, said, "We're focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration."

GRAIL Stock Price and Market Impact
Metric	Value
Close on Feb. 19, 2026	$101.53
Close on Feb. 20, 2026	$50.21
Single-session decline	50.55%
Market capitalization erased	Over $2.2 billion

Figures as reported in the source.

Impacts

Investors who purchased or acquired GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered significant losses may be affected. They have until August 4, 2026, to ask the court to appoint them as lead plaintiff.

The lawsuit could potentially recover losses for affected investors if the allegations are proven. The outcome of the case may also influence how GRAIL and other companies disclose clinical trial data in the future.

Whistleblowers with non-public information regarding GRAIL may consider options to help in the investigation or take advantage of the SEC Whistleblower program, which offers rewards totaling up to 30 percent of any successful recovery made by the SEC.

Future Outlook

Scenario analysis: The possibilities below are not certain predictions.

If the court appoints a lead plaintiff and the case proceeds, the litigation could take months or years to resolve. The outcome may depend on evidence regarding when GRAIL knew about the timeline issues.

If the allegations are proven, GRAIL could face significant financial liability, potentially affecting its stock price and operations. However, if the case is dismissed or settled, the impact on investors may be limited.

The SEC whistleblower program could lead to additional regulatory actions if original information is provided. The future of GRAIL's NHS-Galleri trial and its regulatory approvals may also be influenced by the litigation and public scrutiny.

Source: prnewswire.com

AMRIT EXPLAINER